Literature DB >> 28827419

Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species.

Wiley A Schell1, A M Jones2, Katyna Borroto-Esoda3, Barbara D Alexander4.   

Abstract

SCY-078 in vitro activity was determined for 178 isolates of resistant or susceptible Candida albicans, Candida dubliniensis, Candida glabrata, Candida krusei, Candida lusitaniae, and Candida parapsilosis, including 44 Candida isolates with known genotypic (FKS1 or FKS2 mutations), phenotypic, or clinical resistance to echinocandins. Results were compared to those for anidulafungin, caspofungin, micafungin, fluconazole, and voriconazole. SCY-078 was shown to have excellent activity against both wild-type isolates and echinocandin- and azole-resistant isolates of Candida species.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Candida; antifungal agents; antifungal resistance

Mesh：

Substances：

Year:  2017        PMID： 28827419      PMCID： PMC5655100          DOI： 10.1128/AAC.01102-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

Review 1.  Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004-2008.

Authors:  Michael Pfaller; Dionissios Neofytos; Daniel Diekema; Nkechi Azie; Herwig-Ulf Meier-Kriesche; Shun-Ping Quan; David Horn
Journal:  Diagn Microbiol Infect Dis       Date:  2012-10-25       Impact factor: 2.803

2.  Discovery of a novel class of orally active antifungal beta-1,3-D-glucan synthase inhibitors.

Authors:  Scott S Walker; Yiming Xu; Ilias Triantafyllou; Michelle F Waldman; Cara Mendrick; Nathaniel Brown; Paul Mann; Andrew Chau; Reena Patel; Nicholas Bauman; Christine Norris; Barry Antonacci; Maya Gurnani; Anthony Cacciapuoti; Paul M McNicholas; Samuel Wainhaus; R Jason Herr; Rongze Kuang; Robert G Aslanian; Pauline C Ting; Todd A Black
Journal:  Antimicrob Agents Chemother       Date:  2011-08-15       Impact factor: 5.191

3.  Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model.

Authors:  Alexander J Lepak; Karen Marchillo; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

4.  International study of the prevalence and outcomes of infection in intensive care units.

Authors:  Jean-Louis Vincent; Jordi Rello; John Marshall; Eliezer Silva; Antonio Anzueto; Claude D Martin; Rui Moreno; Jeffrey Lipman; Charles Gomersall; Yasser Sakr; Konrad Reinhart
Journal:  JAMA       Date:  2009-12-02       Impact factor: 56.272

5.  A first Portuguese epidemiological survey of fungaemia in a university hospital.

Authors:  S Costa-de-Oliveira; C Pina-Vaz; D Mendonça; A Gonçalves Rodrigues
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-19       Impact factor: 3.267

6.  A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.

Authors:  Guillermo Garcia-Effron; Santosh K Katiyar; Steven Park; Thomas D Edlind; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

7.  Set of classical PCRs for detection of mutations in Candida glabrata FKS genes linked with echinocandin resistance.

Authors:  Catiana Dudiuk; Soledad Gamarra; Florencia Leonardeli; Cristina Jimenez-Ortigosa; Roxana G Vitale; Javier Afeltra; David S Perlin; Guillermo Garcia-Effron
Journal:  J Clin Microbiol       Date:  2014-05-14       Impact factor: 5.948

8.  Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST).

Authors:  Michael A Pfaller; Shawn A Messer; Mary R Motyl; Ronald N Jones; Mariana Castanheira
Journal:  J Antimicrob Chemother       Date:  2012-11-28       Impact factor: 5.790

9.  Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis.

Authors:  Stephen A Wring; Ryan Randolph; SeongHee Park; George Abruzzo; Qing Chen; Amy Flattery; Graig Garrett; Michael Peel; Russell Outcalt; Kendall Powell; Michelle Trucksis; David Angulo; Katyna Borroto-Esoda
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

10.  Growth and geographic variation in hospitalizations with resistant infections, United States, 2000-2005.

Authors:  Marya D Zilberberg; Andrew F Shorr; Marin H Kollef
Journal:  Emerg Infect Dis       Date:  2008-11       Impact factor: 6.883
View more
  18 in total

1.  Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model.

Authors:  Annie Lee; Brendan Prideaux; Matthew Zimmerman; Claire Carter; Stephen Barat; David Angulo; Véronique Dartois; David S Perlin; Yanan Zhao
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

2.  Amphotericin B Induction with Voriconazole Consolidation as Salvage Therapy for FKS-Associated Echinocandin Resistance in Candida glabrata Septic Arthritis and Osteomyelitis.

Authors:  William F Wright; Nika Bejou; Ryan K Shields; Kieren Marr; Todd P McCarty; Peter G Pappas
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

3.  In Vitro Activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as Determined by EUCAST Methodology and Comparison with Activity against C. albicans and C. glabrata and with the Activities of Six Comparator Agents.

Authors:  Maiken Cavling Arendrup; Karin Meinike Jørgensen; Rasmus Krøger Hare; Anuradha Chowdhary
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

4.  Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action.

Authors:  Martin Hoenigl; Rosanne Sprute; Amir Arastehfar; John R Perfect; Cornelia Lass-Flörl; Romuald Bellmann; Juergen Prattes; George R Thompson; Nathan P Wiederhold; Mohanad M Al Obaidi; Birgit Willinger; Maiken C Arendrup; Philipp Koehler; Matteo Oliverio; Matthias Egger; Ilan S Schwartz; Oliver A Cornely; Peter G Pappas; Robert Krause
Journal:  Expert Opin Investig Drugs       Date:  2022-06-15       Impact factor: 6.498

5.  In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study.

Authors:  Guillermo Quindós; Katherine Miranda-Cadena; Rosario San-Millán; Katyna Borroto-Esoda; Emilia Cantón; María José Linares-Sicilia; Axel Hamprecht; Isabel Montesinos; Anna Maria Tortorano; Anna Prigitano; Matxalen Vidal-García; Cristina Marcos-Arias; Andrea Guridi; Ferran Sanchez-Reus; Jesús Machuca-Bárcena; Manuel Antonio Rodríguez-Iglesias; Estrella Martín-Mazuelos; Carmen Castro-Méndez; Leyre López-Soria; Alba Ruiz-Gaitán; Marcelo Fernandez-Rivero; Damaris Lorenzo; Javier Capilla; Antonio Rezusta; Javier Pemán; Josep Guarro; Joana Pereira; Célia Pais; Orazio Romeo; Guillermo Ezpeleta; Nerea Jauregizar; David Angulo; Elena Eraso
Journal:  Front Cell Infect Microbiol       Date:  2022-05-16       Impact factor: 6.073

6.  Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Aspasia Katragkou; Bo Bo Win Maung; Ethan Naing; Povilas Kavaliauskas; Stephen Barat; Katyna Borroto-Esoda; Nkechi Azie; David Angulo; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

7.  Activity of a novel 1,3-beta-D-glucan Synthase Inhibitor, Ibrexafungerp (formerly SCY-078), Against Candida glabrata.

Authors:  M Ghannoum; L Long; N Isham; C Hager; R Wilson; K Borroto-Esoda; S Barat; D Angulo
Journal:  Antimicrob Agents Chemother       Date:  2019-09-30       Impact factor: 5.191

8.  Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306).

Authors:  R Sobel; P Nyirjesy; M A Ghannoum; D A Delchev; N E Azie; D Angulo; I A Harriott; K Borroto-Esoda; J D Sobel
Journal:  BJOG       Date:  2021-11-08       Impact factor: 7.331

Review 9.  Treatment of Invasive Candidiasis: A Narrative Review.

Authors:  Ronen Ben-Ami
Journal:  J Fungi (Basel)       Date:  2018-08-16

Review 10.  Dermatophyte Resistance to Antifungal Drugs: Mechanisms and Prospectus.

Authors:  Nilce M Martinez-Rossi; Tamires A Bitencourt; Nalu T A Peres; Elza A S Lang; Eriston V Gomes; Natalia R Quaresemin; Maíra P Martins; Lucia Lopes; Antonio Rossi
Journal:  Front Microbiol       Date:  2018-05-29       Impact factor: 5.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.